Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220561 | 1.00 | CA2 (0.61) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL220562 | 1.00 | CA2 (0.61) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL7875753 | 0.83 | CA2 (0.59) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL619199 | 0.81 | CA2 (0.58) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL8182426 | 0.81 | CA2 (0.58) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL9284397 | 0.81 | CA2 (0.58) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL5989989 | 0.80 | CA2 (0.41) | CA2 | |
| SCHEMBL5989992 | 0.80 | CA2 (0.41) | CA2 | |
| SCHEMBL220982 | 0.80 | CA2 (0.49) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL220983 | 0.80 | CA2 (0.49) | CA2ALDH1A1NPSR1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604051-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2013-12-10 | — | — | US | claimed |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2013-06-13 | — | — | US | claimed |
| US-8394822-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-12 | — | — | US | claimed |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2012-12-27 | — | — | US | claimed |
| US-8283359-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2012-10-09 | — | — | US | claimed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | claimed |
| US-7060856-B2 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY (US) | 2006-06-13 | — | — | US | claimed |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3624796-B1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20050085550-A1 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY | 2005-04-21 | — | — | US | disclosed |
| US-20040147478-A1 | Combination chemotherapy | PFIZER INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| CN-1446197-A | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | CN | disclosed |
| EP-0242482-B1 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1995-09-06 | — | — | EP | disclosed |
| US-4965270-A | Viricides | BEECHAM GROUP P.L.C. (GB) | 1990-10-23 | — | — | US | disclosed |
| EP-0242482-A2 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085550-A1 | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | HLA-DRB1, UGT1A3, BBC3 | CA2 3965/4885ALDH1A1 118/4885NPSR1 1016/4885 |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, PRKDC, MAPK1 | CA2 2525/4885ALDH1A1 450/4885NPSR1 3155/4885 |
| US-20250034137-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | CA2 3995/4885ALDH1A1 527/4885NPSR1 3444/4885 |
| US-12065439-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | CA2 3995/4885ALDH1A1 527/4885NPSR1 3444/4885 |
| US-12428418-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | CA2 3995/4885ALDH1A1 527/4885NPSR1 3444/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | CA2 772/4885ALDH1A1 200/4885NPSR1 2165/4885 |
| US-20120329774-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | CA2 4485/4885ALDH1A1 2577/4885NPSR1 4108/4885 |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | CA2 4485/4885ALDH1A1 2577/4885NPSR1 4108/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | CA2 1808/4885ALDH1A1 479/4885NPSR1 1741/4885 |
| US-20130150573-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAPK1, MAP3K6 | CA2 3892/4885ALDH1A1 2344/4885NPSR1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.